Thomas Monath

Summary

Affiliation: Acambis Inc
Country: USA

Publications

  1. pmc ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy
    Juan Arroyo
    Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    J Virol 78:12497-507. 2004
  2. ncbi request reprint Recombination and flavivirus vaccines: a commentary
    Thomas P Monath
    Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Vaccine 23:2956-8. 2005
  3. pmc Lack of transmission of vaccinia virus
    James H Stark
    Emerg Infect Dis 12:698-700. 2006
  4. ncbi request reprint Prospects for development of a vaccine against the West Nile virus
    T P Monath
    Research and Medical Affairs, Acambis Incorporated, Cambridge, Massachusetts 02139, USA
    Ann N Y Acad Sci 951:1-12. 2001
  5. ncbi request reprint Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys
    Thomas P Monath
    Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Biologicals 33:131-44. 2005
  6. ncbi request reprint ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense
    Thomas P Monath
    Acambis Inc, 38, Sidney Street, Cambridge, MA 02139, USA
    Int J Infect Dis 8:S31-44. 2004
  7. ncbi request reprint West Nile virus vaccine
    T P Monath
    Acambis Inc, 38 Sidney Street, Cambridge, Massachusetts 02139, USA
    Curr Drug Targets Infect Disord 1:37-50. 2001
  8. ncbi request reprint Yellow fever vaccine
    Thomas P Monath
    Acambis, Inc, 38 Sidney Street, MA 02139, USA
    Expert Rev Vaccines 4:553-74. 2005
  9. pmc A live, attenuated recombinant West Nile virus vaccine
    Thomas P Monath
    Acambis, 38 Sidney Street, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 103:6694-9. 2006
  10. ncbi request reprint Yellow fever 17D vaccine safety and immunogenicity in the elderly
    Thomas P Monath
    Acambis, Cambridge, Massachusetts 02139, USA
    Hum Vaccin 1:207-14. 2005

Research Grants

Collaborators

Detail Information

Publications60

  1. pmc ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy
    Juan Arroyo
    Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    J Virol 78:12497-507. 2004
    ..The safety, immunogenicity, and efficacy of the ChimeriVax-WN(02) vaccine in the macaque model indicate the vaccine candidate is expected to be safe and immunogenic for humans...
  2. ncbi request reprint Recombination and flavivirus vaccines: a commentary
    Thomas P Monath
    Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Vaccine 23:2956-8. 2005
  3. pmc Lack of transmission of vaccinia virus
    James H Stark
    Emerg Infect Dis 12:698-700. 2006
  4. ncbi request reprint Prospects for development of a vaccine against the West Nile virus
    T P Monath
    Research and Medical Affairs, Acambis Incorporated, Cambridge, Massachusetts 02139, USA
    Ann N Y Acad Sci 951:1-12. 2001
    ..The chimeric virus replicates in the host like yellow fever 17D but immunizes specifically against West Nile virus...
  5. ncbi request reprint Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys
    Thomas P Monath
    Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Biologicals 33:131-44. 2005
    ..The test in infant mice is particularly useful as a means of demonstrating biological consistency across seed virus and vaccine lots...
  6. ncbi request reprint ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense
    Thomas P Monath
    Acambis Inc, 38, Sidney Street, Cambridge, MA 02139, USA
    Int J Infect Dis 8:S31-44. 2004
    ..The vaccines produced major cutaneous reactions and evoked neutralizing antibody and cell-mediated immune responses in the vast majority of subjects and had a reactogenicity profile similar to that of Dryvax...
  7. ncbi request reprint West Nile virus vaccine
    T P Monath
    Acambis Inc, 38 Sidney Street, Cambridge, Massachusetts 02139, USA
    Curr Drug Targets Infect Disord 1:37-50. 2001
    ....
  8. ncbi request reprint Yellow fever vaccine
    Thomas P Monath
    Acambis, Inc, 38 Sidney Street, MA 02139, USA
    Expert Rev Vaccines 4:553-74. 2005
    ....
  9. pmc A live, attenuated recombinant West Nile virus vaccine
    Thomas P Monath
    Acambis, 38 Sidney Street, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 103:6694-9. 2006
    ..ChimeriVax-WN02 rapidly elicits strong immune responses after a single dose, and is a promising candidate warranting further evaluation for prevention of WN disease...
  10. ncbi request reprint Yellow fever 17D vaccine safety and immunogenicity in the elderly
    Thomas P Monath
    Acambis, Cambridge, Massachusetts 02139, USA
    Hum Vaccin 1:207-14. 2005
    ..The neutralizing antibody response, which is the mediator of protective immunity to YF, is not diminished in healthy, elderly persons...
  11. ncbi request reprint Prevention of yellow fever in persons traveling to the tropics
    Thomas P Monath
    Research and Medical Affairs, Acambis, Cambridge, MA 02139, USA
    Clin Infect Dis 34:1369-78. 2002
    ..To avoid unnecessary vaccination, physicians should vaccinate persons at risk on the basis of knowledge of the epidemiology of the disease, reports of epidemic activity, season, and the likelihood of exposure to vector mosquitoes...
  12. ncbi request reprint Yellow fever as an endemic/epidemic disease and priorities for vaccination
    T P Monath
    Acambis, 38 Sidney Street, Cambridge MA 01451, USA
    Bull Soc Pathol Exot 99:341-7. 2006
    ..However, vaccine policy in non-endemic coastal regions of South America must weigh the risk of vaccine-related adverse events against the theoretical benefit of preventing urban yellow fever...
  13. pmc Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines
    Thomas P Monath
    Acambis Inc, Cambridge, Massachusetts 02139, USA
    J Virol 76:1932-43. 2002
    ..These results are consistent with the observation that empirically derived vaccines developed by mouse brain passage of dengue and YF viruses have increased neurovirulence for mice but reduced viscerotropism for humans...
  14. ncbi request reprint Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen
    Thomas P Monath
    Acambis Inc, Cambridge, Massachusetts, USA
    J Infect Dis 188:1213-30. 2003
    ..Anamnestic responses were observed in preimmune individuals. ChimeriVax-JE appears to be a safe vaccine that provides protective levels of neutralizing antibody after a single dose...
  15. ncbi request reprint A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus
    Caroline C Maier
    Virology Department, Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Virology 362:468-74. 2007
    ..A possible interpretation of these observations is that M can modulate the envelope (E) protein function during cell infection...
  16. ncbi request reprint Traditional and novel approaches to flavivirus vaccines
    Konstantin V Pugachev
    Acambis, Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Int J Parasitol 33:567-82. 2003
    ..Other approaches, such as the construction of protein subunit, expression vector-based and naked DNA vaccines, have been proposed to create alternate vaccine candidates...
  17. pmc High fidelity of yellow fever virus RNA polymerase
    Konstantin V Pugachev
    Acambis, Inc, Cambridge, Massachusetts 02139, USA
    J Virol 78:1032-8. 2004
    ....
  18. pmc Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen
    Patricia Londoño-Arcila
    Acambis Ltd, Cambridge, United Kingdom
    Infect Immun 70:5096-106. 2002
    ..The significance of these findings with regard to development of a human vaccine against H. pylori and modulation of immune responses by heterologous prime-boost immunization regimens is discussed...
  19. ncbi request reprint Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool
    Konstantin V Pugachev
    Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Am J Trop Med Hyg 71:639-45. 2004
    ..These chimeras have the potential for use as diagnostic reagents and vaccines against SLE and WN...
  20. ncbi request reprint Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections
    Thomas P Monath
    Research and Medical Affairs, Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Vaccine 20:1004-18. 2002
    ..The new vaccine holds promise for prevention of JE in travelers and residents of endemic countries. The ChimeriVax technology platform is being exploited for development of new vaccines against dengue and West Nile...
  21. ncbi request reprint Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE)
    Konstantin V Pugachev
    Acambis, Inc, 38 Sidney St, Cambridge, MA 02139, USA
    Vaccine 25:6661-71. 2007
    ..These data provide strong experimental evidence that the potential of recombinants, should they ever emerge, to cause disease or spread (compete in nature with wild-type flaviviruses) would be indeed extremely low...
  22. ncbi request reprint Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial
    Thomas P Monath
    Acambis, Cambridge Massachusetts 02139, USA
    Am J Trop Med Hyg 66:533-41. 2002
    ..Adverse events were less frequent in individuals with preexisting immunity to YF, indicating a relationship to virus replication...
  23. ncbi request reprint Pathogenesis and pathophysiology of yellow fever
    Thomas P Monath
    Acambis Inc and Department of Microbiology and Immunology, Harvard School of Public Health, Cambridge, Massachusetts 02139, USA
    Adv Virus Res 60:343-95. 2003
    ....
  24. ncbi request reprint Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes
    Farshad Guirakhoo
    Acambis, Inc, Cambridge, Massachusetts 02139, USA
    Hum Vaccin 2:60-7. 2006
    ..The latter observation can have practical implications toward development of a dengue vaccine...
  25. ncbi request reprint Clonal vaccinia virus grown in cell culture as a new smallpox vaccine
    Richard Weltzin
    Acambis Inc, 38 Sidney Street, Cambridge, Massachusetts 02139, USA
    Nat Med 9:1125-30. 2003
    ..The vaccines were equivalent in their ability to produce major cutaneous reactions ('takes') and to induce neutralizing antibody and cell-mediated immunity against vaccinia virus...
  26. ncbi request reprint New developments in flavivirus vaccines with special attention to yellow fever
    Konstantin V Pugachev
    Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Curr Opin Infect Dis 18:387-94. 2005
    ..We emphasize the need for stepped-up efforts to stop further spread and intensification of these infections worldwide...
  27. doi request reprint Possible autoimmune reactions following smallpox vaccination: the biologic false positive test for syphilis
    Thomas P Monath
    Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, United States
    Vaccine 27:1645-50. 2009
    ..One subject with myocarditis was RPR-negative. One RPR-positive and 1 RPR-negative subject had elevated CK-MB enzymes without other evidence for myocarditis...
  28. ncbi request reprint Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing
    Konstantin V Pugachev
    Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Vaccine 20:996-9. 2002
    ..e. did not result in an amino acid change). The differences are inconsequential to safety and effectiveness of ARILVAX. Other YF 17D vaccines are undoubtedly also heterogeneous and need to be re-examined using the consensus approach...
  29. pmc Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A
    Samer Aboudola
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Infect Immun 71:1608-10. 2003
    ..These findings support the feasibility of using a vaccine to protect high-risk individuals against C. difficile-associated diarrhea and colitis...
  30. ncbi request reprint Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea
    Stavros Sougioultzis
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 02215, USA
    Gastroenterology 128:764-70. 2005
    ..Our aim was to examine whether the vaccine is also well tolerated and immunogenic in patients with recurrent CDAD...
  31. ncbi request reprint Editorial: jennerian vaccination against West Nile virus
    Thomas P Monath
    Am J Trop Med Hyg 66:113-4. 2002
  32. ncbi request reprint Viral vectors for malaria vaccine development
    Shengqiang Li
    PATH Malaria Vaccine Initiative, Bethesda, MD, USA
    Vaccine 25:2567-74. 2007
    ..Understanding the vector's ability to induce an immune response and the expression of malaria antigens in mammalian cells will be critical in designing the next generation of viral-vectored malaria vaccines...
  33. ncbi request reprint Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates
    Cheryl H Dean
    BD Technologies, Research Triangle Park, North Carlina, USA
    Hum Vaccin 1:106-11. 2005
    ..Thus, cutaneous delivery may represent a minimally-invasive alternative approach for flavivirus vaccines that more closely resembles the natural route of viral infection...
  34. ncbi request reprint Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE)
    Mark Reid
    Australian Army Malaria Institute, Brisbane, Queensland, Australia
    Am J Trop Med Hyg 75:659-63. 2006
    ..vigilax was infected when fed on YF 17D. The results suggest that none of these three species of mosquito are likely to set up secondary cycles of transmission of ChimeriVax-JE in Australia after feeding on a viremic vaccinee...
  35. ncbi request reprint Exercise-induced serum enzyme elevations confounding the evaluation of investigational drug toxicity. Report of two cases in a vaccine trial
    Casey Johnson
    Pharmaceutical Research Associates Inc, Lenexa, Kansas, USA
    Hum Vaccin 1:24-9. 2005
    ..The inclusion of placebo control arm (in lieu of or addition to an active vaccine control) will also be useful in differentiating causally related serum enzyme elevations...
  36. ncbi request reprint Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand
    Stephen Higgs
    Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555 0609, USA
    Am J Trop Med Hyg 75:986-93. 2006
    ..Considering the low level viremias anticipated in humans vaccinated with these viruses, it is predicted that the risks of infection and transmission by mosquitoes in nature is minimal...
  37. ncbi request reprint Dengue and yellow fever--challenges for the development and use of vaccines
    Thomas P Monath
    Kleiner Perkins Caulfield and Byers, Menlo Park, CA, USA
    N Engl J Med 357:2222-5. 2007
  38. ncbi request reprint Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge
    Kathleen A Marriott
    Battelle Biomedical Research Center, West Jefferson, OH 43162, USA
    Vaccine 26:581-8. 2008
    ..The protective efficacy of ACAM2000 was found to be equivalent to the currently approved vaccine, Dryvax...
  39. doi request reprint Safety of flavivirus chimeric vaccines: answer to Ishikawa et al. [Vaccine 26 (22) (2008) 2772-2781]
    Bruno Guy
    Vaccine 26:4107-8. 2008
  40. doi request reprint Yellow fever: 100 years of discovery
    J Erin Staples
    Arboviral Diseases Branch, Division of Vector Borne Infectious Diseases, Centers for Disease Control and Prevention, 3150 Rampart Rd, Fort Collins, CO 80521, USA
    JAMA 300:960-2. 2008
  41. ncbi request reprint 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005
    Alan D T Barrett
    Sealy Centre for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555 0609, USA
    Vaccine 25:2758-65. 2007
    ....
  42. ncbi request reprint Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes
    Barbara W Johnson
    Division of Vector Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado 80522, USA
    Am J Trop Med Hyg 67:260-5. 2002
    ..Therefore, transmission of ChimeriVax-DEN2 virus by vector mosquitoes is unlikely...
  43. ncbi request reprint Host-range restriction of chimeric yellow fever-West Nile vaccine in fish crows (Corvus ossifragus)
    Stanley A Langevin
    Centers for Disease Control and Prevention, Fort Collins, Colorado 80522, USA
    Am J Trop Med Hyg 69:78-80. 2003
    ..However, if used in mammals, this recombinant viral vaccine is unlikely to inadvertently enter a natural transmission cycle with birds as amplifying hosts...
  44. ncbi request reprint Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis
    CHING JUH LAI
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Adv Virus Res 61:469-509. 2003
    ..The chimeric flavivirus strategy has led to the rapid development of novel live-attenuated vaccines against dengue, TBE, JE, and West Nile viruses...
  45. ncbi request reprint High rates of recurrence and of transient reinfections of Helicobacter pylori in a population with high prevalence of infection
    Yelda Leal-Herrera
    Unidad de Investigacion en Enfermedades Infecciosas, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
    Am J Gastroenterol 98:2395-402. 2003
    ..pylori) infection after eradication treatment. The aims of this study were to determine the magnitude of H. pylori reinfection versus recrudescence, and to identify possible risk factors for reinfection...
  46. ncbi request reprint Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine
    David W C Beasley
    Department of Pathology, Sealy Center for Vaccine Development, and Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555 0609, USA
    Vaccine 22:3722-6. 2004
    ..ChimeriVax-JE stimulated protection that was comparable or superior to the JE-VAX control...
  47. ncbi request reprint Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction
    Barbara W Johnson
    Division of Vector Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado 80521, USA
    Am J Trop Med Hyg 70:89-97. 2004
    ..Therefore, it is unlikely that a mosquito feeding on a viremic vaccinee, would become infected with the chimeric viruses. Thus, there is very little potential for transmission by mosquitoes of the ChimeriVax-DEN vaccine viruses...
  48. pmc Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model
    Robert B Tesh
    University of Texas Medical Branch, Galveston 77555, USA
    Emerg Infect Dis 8:1392-7. 2002
    ....
  49. ncbi request reprint Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells
    Samantha Brandler
    Institute of Virology, Medical University of Vienna, Vienna, Austria
    Am J Trop Med Hyg 72:74-81. 2005
    ..The lack of growth of chimeric viruses in human hepatic cells suggests that these viruses may be less hepatotropic than YF 17D virus vaccine in humans...
  50. ncbi request reprint Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru
    Vivian E Belmusto-Worn
    U S Naval Medical Research Center Detachment, Lima, Peru
    Am J Trop Med Hyg 72:189-97. 2005
    ..There were no treatment-related serious AEs. This is the first randomized, double-blind comparison of two YF vaccines in a pediatric population; both vaccines were shown to be highly immunogenic and well-tolerated...
  51. ncbi request reprint Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori
    Stavros Sougioultzis
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Vaccine 21:194-201. 2002
    ..In conclusion, rectal delivery of 5 microg LT is safe and induces vigorous systemic anti-LT immune responses. Further studies are needed to determine if LT can be an effective adjuvant for rectally delivered antigens...
  52. ncbi request reprint A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults
    Andrew W Artenstein
    Center for Biodefense and Emerging Pathogens, Division of Infectious Diseases, Memorial Hospital of Rhode Island, Pawtucket, USA
    Vaccine 23:3301-9. 2005
    ..One subject who received ACAM2000 developed myopericarditis. In healthy, primary vaccines ACAM2000 has a similar vaccination success rate, antibody response, and safety profile to Dryvax...
  53. ncbi request reprint Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002
    Martin S Cetron
    Division of Global Migration and Quarantine, National Center for Infectious Diseases, CDC, USA
    MMWR Recomm Rep 51:1-11; quiz CE1-4. 2002
    ..cdc.gov/travel/index.htm, and through the website for the Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, CDC, at http://www.cdc.gov/ncidod/ dvbid/yellowfever/index.htm...
  54. ncbi request reprint Epidemiology and ecology of yellow fever virus
    Alan D Barrett
    Center for Biodefense and Emerging Infectious Diseases, Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, Texas 77555 0609, USA
    Adv Virus Res 61:291-315. 2003
  55. ncbi request reprint Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy
    Giselle Soto
    Asociacion Benefica PRISMA, Lima, Peru
    J Infect Dis 188:1263-75. 2003
    ..Although eradication with antibiotics was successful, the high rate of reinfection suggests that treatment is unlikely to have a lasting public health effect in this setting...
  56. ncbi request reprint Preface to the flaviviruses
    Thomas J Chambers
    Adv Virus Res 60:ix-xi. 2003
  57. ncbi request reprint Treatment of yellow fever
    Thomas P Monath
    Kleiner Perkins Caufield and Byers, Menlo Park, CA, United States
    Antiviral Res 78:116-24. 2008
    ....
  58. ncbi request reprint Preface to volume 60 the flaviviruses: pathogenesis and immunity
    Thomas J Chambers
    Adv Virus Res 60:xiii-xiv. 2003
  59. ncbi request reprint Specific immunoglobulin A antibodies in maternal milk and delayed Helicobacter pylori colonization in Gambian infants
    Julian E Thomas
    Medical Research Council Human Nutrition Research, Keneba, The Gambia
    Clin Infect Dis 39:1155-60. 2004
    ..Immunoglobulin A (IgA) in maternal milk may protect Gambian infants from early Helicobacter pylori colonization. This study sought evidence that this protection could be due to specific IgA antibodies...
  60. ncbi request reprint Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions
    Getahun Abate
    Department of Internal Medicine, Saint Louis University, St Louis, Missouri 63110, USA
    J Infect Dis 192:1362-71. 2005
    ..CFSE-based flow-cytometric assays will be useful in evaluating cell-mediated immune responses induced by new smallpox vaccines...

Research Grants3

  1. LIVE, ATTENUATED, RECOMBINANT VACCINE - WEST NILE VIRUS
    Thomas Monath; Fiscal Year: 2002
    ..abstract_text> ..